Form D · Biotechnology
MyoKardia Inc
South San Francisco, CA · CIK 0001552451
Offering snapshot reported Apr 30, 2015 · SEC filing
- Reported sold
- $46M Offering amount: $46M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 20, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 30, 2015 | Initial | $46,000,001 | No comparison | 9 | SEC filing |
| Aug 22, 2014 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Oct 3, 2012 | Initial | $459 | No comparison | 6 | SEC filing |
| Oct 3, 2012 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
| Jul 5, 2012 | Initial | $200 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-238915
Source: Form D, filed Apr 30, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Katherine Bowdish | Director |
| Tassos Anastasios Gianakakos | Director, Executive |
| Charles Homcy | Director |
| Mark Perry | Director |
| Kevin Starr | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
333 Allerton Avenue
South San Francisco, CA, 94080
South San Francisco, CA, 94080